Milameline (CI-979 PD-129409 RU-35926) is a non-selective muscarinic acetylcholine receptor partial agonist with cognition-acting properties that was being investigated for the treatment of Alzheimer’s disease but produced poor results in clinical trials and was subsequently discontinued.
This page contains content from the copyrighted Wikipedia article "Milameline"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
